Takeda Canada announce that Health Canada has authorized LIVTENCITY™ (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies. Compared to conventionally used antivirals to treat post-transplant CMV, LIVTENCITY offers twice the efficacy and more than 10 times less toxicity. The approval of LIVTENCITY is based on the SOLSTICE Study, which assessed the efficacy and safety of LIVTENCITY treatment compared to Investigator Assigned Treatment (IAT) in 350 Hematopoietic Stem Cell Transplant (HSCT) and Solid Organ Transplant (SOT) recipients with CMV infections that were refractory to treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir–including CMV infections with or without confirmed resistance to 1 or more anti-CMV agents. Beneficial treatment effect was consistent regardless of transplant type, baseline CMV DNA viral load, genotypic resistance, CMV syndrome at baseline and age.